Of clinical relevance is our finding that the PS-flippase and evectin-2/Nedd4 E3 ligase were active in an aggressive metastatic breast cancer cell line, which could lead to new drug targets for cancers in which the malignancy depends on YAP function. Here, PLEKHB2 is linked to breast carcinoma.